Search - tctmd.com

Displaying 581 - 600 of 988

Sort: Relevancy | Date

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Caitlin E. Cox

January 29, 2019

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

Caitlin E. Cox

January 28, 2019

News Conference News ISET 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

Caitlin E. Cox

January 28, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

AAA Rupture Rate in England Supports Current Thresholds for Surveillance, Intervention—With Some Caveats

Shelley Wood

January 21, 2019

News Daily News

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Michael O'Riordan

January 17, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

Cardiac Complications Are a Common Cause of Readmission Following Endovascular AAA Interventions

Yael L. Maxwell

January 02, 2019

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Features

Year in Review: Physicians Pick the Biggest News of 2018

TCTMD News Team

December 29, 2018

News Features

Top News in Endovascular Therapy: 2018

L.A. McKeown

December 28, 2018

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Daily News

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

L.A. McKeown

December 17, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Daily News

NICE Revisits UK Stroke Guidance, Including Thrombectomy

Caitlin E. Cox

November 30, 2018

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

Advertisement

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

AAA Rupture Rate in England Supports Current Thresholds for Surveillance, Intervention—With Some Caveats

FDA Alerts Doctors to Potential Late Risks With Paclitaxel-Coated Balloons and Stents in PAD

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Cardiac Complications Are a Common Cause of Readmission Following Endovascular AAA Interventions

The Biggest News of 2018: TCTMD’s Top 10

Year in Review: Physicians Pick the Biggest News of 2018

Top News in Endovascular Therapy: 2018

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Two Trials Halted in Wake of Study Linking Paclitaxel-Coated Devices to Deaths in PAD

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

NICE Revisits UK Stroke Guidance, Including Thrombectomy

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content